Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
Clinical Immunology | Spotlight

Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort

Arlene E. Dent, Indu Malhotra, Xuelie Wang, Denise Babineau, Kee Thai Yeo, Timothy Anderson, Rhonda J. Kimmel, Evelina Angov, David E. Lanar, David Narum, Sheetij Dutta, Jack Richards, James G. Beeson, Brendan S. Crabb, Alan F. Cowman, Toshihiro Horii, Eric Muchiri, Peter L. Mungai, Christopher L. King, James W. Kazura
P. P. Wilkins, Editor
Arlene E. Dent
aCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA
bDepartment of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Indu Malhotra
aCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuelie Wang
cDepartment of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise Babineau
cDepartment of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kee Thai Yeo
bDepartment of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Anderson
dSchool of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rhonda J. Kimmel
aCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelina Angov
eMalaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Lanar
eMalaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Narum
fLaboratory of Malaria Immunology and Vaccinology, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheetij Dutta
eMalaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Richards
gBurnet Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James G. Beeson
gBurnet Institute, Melbourne, Australia
hDepartment of Microbiology, Monash University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brendan S. Crabb
gBurnet Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan F. Cowman
iWalter and Eliza Hall Institute of Medical Research, Parkville, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshihiro Horii
jDepartment of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Muchiri
kDivision of Vector Borne and Neglected Tropical Diseases, Ministry of Public Health and Sanitation, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter L. Mungai
aCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA
kDivision of Vector Borne and Neglected Tropical Diseases, Ministry of Public Health and Sanitation, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher L. King
aCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James W. Kazura
aCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. P. Wilkins
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CVI.00452-15
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Serological responses in infants over time. (A) Detection probability (y axis) of each antibody in infants over time (x axis). Responses to specific antigens are indicated in each plot box. (B) Magnitude of antibodies in cord blood for each indicated antigen expressed as fold increase relative to negative-control North Americans (NAm) (mean + standard error of the mean).

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Infant VSA, GIA, and IIA antibodies over time. (A) Detection probability (y axis) of each VSA measured antibody response in infants over time (x axis). VSA responses to each P. falciparum isolate are indicated. Bar graph to the right of the plot shows the geometric mean fluorescence intensity (GeoMFI) for VSA antibodies in cord blood (mean + standard error of the mean [SEM]). (B) Detection probability (y axis) of W2mef and D10 GIA antibody responses in infants over time (x axis). Bar graph to the right of the plot shows the percentage of growth inhibition of GIA responses in cord blood (mean + SEM). (C) Detection probability (y axis) of Sial Dep and MSP1-19 IIA antibody responses in infants over time (x axis). Bar graph to the right of the plot shows the percentage of invasion inhibition responses in cord blood (mean + SEM).

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Antibodies in cord blood (open circles) compared to 36-month-old young children (open triangles). Dot plots of serologic antibody responses (fold increase relative to North Americans [NAm]) to specified antigens measured in cord blood and 36-month-old young children (A) and to another set of antigens measured in cord blood and 36-month-old young children (B). Note the smaller y axis in (B) than in (A). (C) GeoMFI of VSA responses measured in cord blood and 36-month-old young children. (D) Percent growth inhibition of GIA and IIA antibody responses measured in cord blood and 36-month-old young children. *, P = 0.04; **, P = 0.0005; ***, P = 0.0002; ****, P < 0.0001; horizontal bar when visible represents median values.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Magnitude and prevalence of IgG antibodies in cord blood

    Assay/antigen tested (P. falciparum isolate)Sample size (no.)Mean (SD)/median (IQRa)No. (%) positive
    Serology (fold increase in MFI over negative controls)
        LSA17824.7 (42.6)/4.7 (1.6–27.8)59 (75.6)
        CSP7829.5 (39.7)/11.4 (3.3–40.0)68 (87.2)
        PfCelTOS780.6 (1.4)/0.0 (0.0–0.0)15 (19.2)
        SE50780.6 (2.1)/0.0 (0.0–0.0)11 (14.1)
        SE36783.1 (6.9)/0.0 (0.0–2.6)34 (43.6)
        MSP142 (3D7)789.3 (11.9)/5.8 (0.0–12.0)58 (74.4)
        MSP142 (FVO)786.5 (9.5)/2.3 (0.0–10.6)46 (59.0)
        MSP142 (FUP)7812.2 (13.8)/6.8 (2.4–16.6)68 (87.2)
        EBA140788.7 (19.6)/1.7 (0.0–7.3)41 (52.6)
        EBA175789.9 (14.7)/3.7 (0.0–14.5)49 (62.8)
        EBA181789.6 (17.9)/2.7 (0.0–8.6)51 (65.4)
        AMA1 (3D7)7881.0 (46.4)/88.1 (48.4–101.6)76 (97.4)
        AMA1 (FVO)7896.7 (61.2)/113.9 (39.5–131.2)76 (97.4)
    Variant surface antigen assay (geometric mean MFI)
        BFD 20067940.2 (56.4)/17.0 (11.0–46.0)42 (53.8)
        Msambweni 20067937.4 (40.9)/21.0 (13.0–44.0)54 (69.2)
        3D77924.2 (28.0)/13.5 (8.0–30.0)37 (47.4)
    Growth and invasion inhibition assay (percent inhibition)
        Sial Dep IIA842.8 (7.5)/0.0 (0.0–0.0)12 (14.6)
        W2mef GIA8411.3 (15.6)/6.0 (0.0–19.6)31 (37.8)
        MSP1-19 IIA840.8 (2.7)/0.0 (0.0–0.0)5 (6.1)
        D10 GIA844.2 (8.5)/0.0 (0.0–4.6)18 (22.0)
    • ↵a IQR, interquartile range.

  • TABLE 2

    IgG antibody rates of change before and after 6 months of age

    Assay/antigen tested (P. falciparum isolate)Time periodOdds ratio (95% CIa) per 1 mo age changePP difference between rates of changeb
    Serology
        LSA1Before 6 moc0.72 (0.65–0.80)<0.001<0.001
    After 6 mod1.04 (1.02–1.07)<0.001
        CSPBefore 6 mo0.64 (0.57–0.72)<0.001<0.001
    After 6 mo1.04 (1.02–1.06)<0.001
        PfCelTOSBefore 6 mo1.16 (1.04–1.28)<0.0010.08
    After 6 mo1.05 (1.03–1.07)<0.001
        SE50Before 6 mo1.20 (1.07–1.34)0.00250.03
    After 6 mo1.04 (1.02–1.06)<0.001
        SE36Before 6 mo0.88 (0.80–0.98)0.010.003
    After 6 mo1.04 (1.03–1.06)<0.001
        MSP142 (3D7)Before 6 mo0.75 (0.68–0.82)<0.001<0.001
    After 6 mo1.04 (1.02–1.06)<0.001
        MSP142 (FVO)Before 6 mo0.79 (0.73–0.87)<0.001<0.001
    After 6 mo1.05 (1.03–1.08)<0.001
        MSP142 (FUP)Before 6 mo0.66 (0.58–0.74)<0.001<0.001
    After 6 mo1.05 (1.03–1.08)<0.001
        EBA140Before 6 mo0.85 (0.77–0.92)<0.001<0.001
    After 6 mo1.06 (1.04–1.09)<0.001
        EBA175Before 6 mo0.76 (0.70–0.84)<0.001<0.001
    After 6 mo1.05 (1.03–1.07)<0.001
        EBA181Before 6 mo0.75 (0.68–0.82)<0.001<0.001
    After 6 mo1.06 (1.03–1.08)<0.001
        AMA1 (3D7)Before 12 mo0.76 (0.71–0.81)<0.001<0.001
    After 12 mo1.03 (1.01–1.06)0.02
        AMA1 (FVO)Before 12 mo0.79 (0.75–0.83)<0.001<0.001
    After 12 mo1.04 (1.01–1.07)0.003
    Variant surface antigen assay
        BFD 2006Before 6 mo0.76 (0.69–0.84)<0.001<0.001
    After 6 mo1.01 (0.99–1.03)0.33
        Msambweni 2006Before 6 mo0.60 (0.53–0.68)<0.001<0.001
    After 6 mo1.02 (0.98–1.05)0.35
        3D7Before 6 mo0.63 (0.55–0.73)<0.001<0.001
    After 6 mo1.01 (0.97–1.05)0.63
    Growth and invasion inhibition assay
        Sial Dep IIABefore 6 mo1.18 (1.04–1.34)0.010.02
    After 6 mo0.98 (0.93–1.04)0.56
        W2mef GIABefore 6 mo0.77 (0.68–0.89)<0.001<0.001
    After 6 mo1.05 (1.00–1.10)0.07
        MSP1-19 IIABefore 12 mo1.03 (0.94–1.13)0.530.31
    After 12 mo0.93 (0.81–1.08)0.35
        D10 GIABefore 12 mo0.86 (0.78–0.95)0.0040.07
    After 12 mo1.05 (0.92–1.19)0.491
    • ↵a CI, confidence interval.

    • ↵b Difference between rates of change between birth to 6 (or 12) months of age and between 6 months of age and 36 months of age (Fisher's exact test).

    • ↵c Compared to cord blood responses.

    • ↵d Compared to 6-month responses.

  • TABLE 3

    Association between presence of IgG antibodies at 12 months of age and first occurrence of a malaria infection after 12 months of age

    Assay/antigen testedNo. testedNo. of malaria eventsHazard ratio (95% confidence interval)P
    Serology
        LSA167171.84 (0.71–4.77)0.21
        CSP67172.64 (1.00–6.97)0.05
        PfCelTOS67172.67 (0.94–7.61)0.07
        SE5067174.51 (1.46–13.9)0.009
        SE3667172.35 (0.89–6.19)0.08
        MSP142 (3D7)67171.90 (0.73–4.99)0.19
        MSP142 (FVO)67174.37 (1.52–12.6)0.006
        MSP142 (FUP)67173.13 (1.14–8.57)0.03
        EBA14067173.27 (1.19–8.95)0.02
        EBA17567173.12 (1.18–8.25)0.02
        EBA18167171.76 (0.68–4.56)0.25
        AMA1 (3D7)67172.98 (1.07–8.33)0.04
        AMA1 (FVO)67176.21 (1.67–23.1)0.006
    Variant surface antigen assay
        BFD 200667172.43 (0.78–7.56)0.13
        Msambweni 200667171.00 (0.13–7.60)1.00
        3D767172.45 (0.56–10.8)0.23
    Growth and invasion inhibition assay
        Sial Dep IIA65171.64 (0.60–4.47)0.34
        W2mef GIA65171.52 (0.49–4.74)0.47
        MSP1-19 IIA65171.56 (0.36–6.84)0.55
        D10 GIA65171.49 (0.20–11.3)0.70

Additional Files

  • Figures
  • Tables
  • Supplemental material

    • Supplemental file 1 -

      Table S1. IgG antibody rates of change before and after 6 months of age in malaria-sensitized versus -not sensitized infants. Fig. S1. Three examples of the raw data for the longitudinal infant cohort. Fig. S2. Detection probability of infant antibodies over time.

      PDF, 214K

PreviousNext
Back to top
Download PDF
Citation Tools
Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort
Arlene E. Dent, Indu Malhotra, Xuelie Wang, Denise Babineau, Kee Thai Yeo, Timothy Anderson, Rhonda J. Kimmel, Evelina Angov, David E. Lanar, David Narum, Sheetij Dutta, Jack Richards, James G. Beeson, Brendan S. Crabb, Alan F. Cowman, Toshihiro Horii, Eric Muchiri, Peter L. Mungai, Christopher L. King, James W. Kazura
Clinical and Vaccine Immunology Feb 2016, 23 (2) 104-116; DOI: 10.1128/CVI.00452-15

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort
Arlene E. Dent, Indu Malhotra, Xuelie Wang, Denise Babineau, Kee Thai Yeo, Timothy Anderson, Rhonda J. Kimmel, Evelina Angov, David E. Lanar, David Narum, Sheetij Dutta, Jack Richards, James G. Beeson, Brendan S. Crabb, Alan F. Cowman, Toshihiro Horii, Eric Muchiri, Peter L. Mungai, Christopher L. King, James W. Kazura
Clinical and Vaccine Immunology Feb 2016, 23 (2) 104-116; DOI: 10.1128/CVI.00452-15
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X